Barclays analyst Matt Miksic raised the firm’s price target on Zimmer Biomet to $120 from $116 and keeps an Underweight rating on the shares. The company reported a solid beat to sales, but the upside was offset by higher spending, and investors were caught off guard by management’s “mixed comments” on 2024, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet raises FY23 adjusted EPS view to $7.47-$7.57 from $7.40-$7.50
- Zimmer Biomet reports Q2 adjusted EPS $1.82, consensus $1.81
- Zimmer Biomet Announces Second Quarter 2023 Financial Results
- ZBH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Zimmer Biomet price target raised to $153 from $147 at Truist